Download March 4, 2016 Bibliography

WELLCOME TRUST-CIDRAP Ebola Vaccine Team B
March 4, 2016 Ebola Vaccine Bibliography
WHO
Questions and Answers. Ebola ça suffit! - Phase III Vaccine Trial in Guinea (Jan. 27, 2016)
Report by the Director-General to the Executive Board at its 138th Session (Jan. 25, 2016)
Ebola Situation Report (Mar. 2, 2016)
Gavi, the Vaccine Alliance
An Ebola vaccine and the future of fighting infectious disease (Seth Berkley, Jan. 22, 2016)
Ebola vaccine purchasing commitment from Gavi to prepare for future outbreaks (Press release, Jan. 20,
2016)
Gavi. Report to the Board: Ebola Update (Agenda item 16, the Gavi Board Meeting page, Dec. 2-3, 2015)
NIAID
Experimental Ebola vaccines well tolerated, immunogenic in phase 2 study (Feb. 23, 2016)
NIAID Role in Ebola and Marburg Research (Web page)
Johnson & Johnson
Our Commitment to Combating Ebola (landing page)
United Nations
Protecting Humanity from Future Health Crises. Report of the High-level Panel on the Global Response to
Health Crises (final report, advance unedited copy), Jan. 25, 2016.
UNICEF
Emergency and Outbreak Response: Updates, Challenges and Opportunities for Vaccine Supply (October
2015)
National Academy of Medicine
Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities
Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington DC: National
Academies Press, 2016.
MEDICAL LITERATURE – REPORTS AND COMMENTARIES
Arnemo M, Watle SSV, Schoultz KM, et al. Stability of a Vesicular Stomatitis Virus–Vectored Ebola Vaccine.
J Infect Dis. (2016) 213(6): 930-933.
Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular and protective
immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine
2016 Feb 24. pii: S0264-410X(16)00196-1. [Epub ahead of print]
WELLCOME TRUST – CIDRAP Ebola Vaccine Team B | 3.4.16 | Page 1 of 4
Bolay F, for the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL 1) Team. A randomized
controlled trial of the safety and immunogenicity of two Ebola vaccines (Abstract 76LB), presented at the
2016 Conference on Retroviruses and Opportunistic Infections, Feb. 22-25, 2016, Boston MA).
Checchi F, Waldman RJ, Roberts LF, et al. World Health Organization and emergency health: if not now,
when? BMJ 2016;352:i469
Currie J, Grenfell B, Farrar J. Beyond Ebola. Science 2016; 351(6275):815-816
Foged C. Thermostable Subunit Vaccines for Pulmonary Delivery: How Close Are We? Curr Pharm
Des. 2016 Feb 2. [Epub ahead of print]
Folayan MO, Peterson K, Kombe F. Ethics, emergencies and Ebola clinical trials: the role of governments
and communities in offshored research. Pan Afr Med. 2015 Oct 10;22 Suppl 1:10.
Folayan MO, Yakubu A, Haire B, et al. Ebola vaccine development plan: ethics, concerns and proposed
measures. BMC Med Ethics. 2016 Feb 8;17(1):10.
Furuyama W, Marzi A, Nanbo A, et al. Discovery of an antibody for pan-ebolavirus therapy. Sci Rep. 2016
Feb 10;6:20514.
Gulland A. Ebola vaccine will be made available for emergency use. BMJ 2016 Jan 22;532:i386.
Huo X, Shi G, Li X, et al. Knowledge and attitudes about Ebola vaccine among the general population in
Sierra Leone. Vaccine 2016 Feb 26. pii: S0264-410X(16)00227-9. [Epub ahead of print]
Jacobsen KH, Aguirre AA, Bailey CL, et al. Lessons from the Ebola Outbreak: Action Items for Emerging
Infectious Disease Preparedness and Response. Ecohealth 2016 Feb 25. [Epub ahead of print]
Lever RA, Whitty CJM. Ebola virus disease: emergence, outbreak and future directions. Br Med Bull. 2016
Feb 12. pii: ldw005. [Epub ahead of print]
Martins KAO, Cooper CL, Stronsky SM, et al. Adjuvant-enhanced CD4 T Cell Responses are Critical to
Durable Vaccine Immunity. EBioMedicine. 2015 Nov 27;3:67-78.
Marzi A, Murphy AA, Feldmann F, et al. Cytomegalovirus-based vaccine expressing Ebola virus
glycoprotein protects nonhuman primates from Ebola virus infection. Sci Rep 2016; 6: 21674
Miller CR, Johnson EL, Burke AZ, et al. Initiating a watch list for Ebola virus antibody escape mutations.
PeerJ 2016 Feb 16;4:e1674.
Quaglio GL, Goerens C, Putoto G, et al. Ebola: lessons learned and future challenges for Europe. Lancet
2016; 16(2):259-263.
Rid A, Miller FG. Ethical Rationale for the Ebola "Ring Vaccination" Trial Design. Am J Public Health. 2016
Jan 21:e1-e4. [Epub ahead of print]
Rizzo A, Pedalino B, Porfiri M. A network model for Ebola spreading. J Theor Biol. 2016 Jan 21. pii: S00225193(16)00048-5.
Sands P, Mundaca-Shah C, Dzau VJ. The Neglected Dimension of Global Security - A Framework for
Countering Infectious-Disease Crises. N Engl J Med. 2016 Jan 13. [Epub ahead of print]
WELLCOME TRUST – CIDRAP Ebola Vaccine Team B | 3.4.16 | Page 2 of 4
Wojda TR, Valenza PL, Cornejo K, et al. The Ebola Outbreak of 2014-2015: From Coordinated Multilateral
Action to Effective Disease Containment, Vaccine Development, and Beyond. J Glob Infect Dis. 2015 OctDec;7(4):127-38.
SCIENCE NEWS
Uganda In Clinical Trials For Ebola Vaccine (IP Watch, March 2, 2016)
Studies on Ebola survivors show range of complications (CIDRAP News, Feb. 25, 2016)
Why the world is stockpiling hundreds of thousands of doses of an unapproved vaccine (Tech Insider, Feb.
24, 2016)
CDC to end Ebola-related screening of travelers from Guinea (CIDRAP News, Feb. 18, 2016)
Russia to test Ebola candidate in Guinea: AFP (Fierce Vaccines, Feb. 16, 2016)
We’ve got the only proven Ebola vaccine, but we’ll share it – Russia’s health minister to RT (RT News, Feb.
16, 2016)
Russia patents Ebola vaccines, has exclusive use rights (Sputnik News, Feb. 15, 2016)
New study highlights effectiveness of a herpesvirus CMV-based vaccine against Ebola (EurekAlert, Feb. 15,
2016)
Russia to present Ebola vaccine at WHO next week (Tass, Feb. 12, 2016)
Researchers present inner workings of Ebola vaccine trial (EurekAlert, Feb. 12, 2016)
Gloomy assessment underpins UN panel's health crisis advice (CIDRAP News, Feb. 9, 2016)
Developing vaccine for Zika to take time: Johnson & Johnson's Paul Stoffels (Economic Times, Feb. 8, 2016)
Russia’s Ebola vaccine to be used in Guinea starting this fall — healthcare minister (Tass, Feb. 5, 2016)
Details emerge about Russia's mysterious Ebola vaccine (Russia Beyond the Headlines, Jan. 29, 2016)
WHO issues Ebola survivor guidance as cases show virus persistence (CIDRAP News, Jan. 22, 2016)
Preventing the Next Ebola Epidemic (Seth Berkley, Scientific American, Jan. 21, 2016)
Sierra Leone implements Ebola vaccination programme (BDlive, Jan. 21 2016)
Prevail Marks One Year Of Ebola Virus Disease Research (Front Page Africa, Jan. 21, 2016)
Davos' Ebola Vaccine Deal Signals A Major Shift In Global Health (Huffington Post, Jan. 21, 2016)
Health Threats Spur Vaccine Hunt (Wall Street Journal, Jan. 21, 2016)
Gavi, Merck ink Ebola vaccine purchase agreement (CIDRAP News, Jan. 20, 2016)
Sierra Leone reports second new Ebola case (CIDRAP News, Jan. 20, 2016)
WELLCOME TRUST – CIDRAP Ebola Vaccine Team B | 3.4.16 | Page 3 of 4
Merck to submit Ebola vaccine for approval by end of 2017 (Bloomberg news, Jan. 20, 2016)
Ebola: $5m vaccine deal announced (BBC News, Jan. 20, 2016)
Profectus BioSciences launches phase 1 clinical trial for Ebola vaccine (Vaccine News Daily, Jan. 20, 2016)
MSF reaction to announcement of Merck and Gavi, the Vaccine Alliance for future Ebola outbreak
preparedness (MSF Access Campaign, Jan. 20, 2016)
Pandemic readiness review says $4.5 billion a year needed (CIDRAP News, Jan. 13, 2016)
WELLCOME TRUST – CIDRAP Ebola Vaccine Team B | 3.4.16 | Page 4 of 4